What Kind of Evidence and Sourcing Does PeptaHub Provide for Each Peptide?

PeptaHub presents itself as an evidence-based peptide reference, and the sourcing model is visible on the page itself: each profile is tied to a stated number of peer-reviewed sources, and the content covers mechanisms of action, research context, reported study ranges, risks, and regulatory status. For example, the BPC-157 profile is labeled with 7 peer-reviewed sources, and the TB-500 profile with 6. If you want a quick read on how well-documented a given peptide is before you dig in, that source count is the first signal to check.

What each profile is built on

According to the site's own description, profiles are assembled from peer-reviewed research rather than user submissions or promotional material. The stated content categories for a profile are:

• Mechanism of action — how the peptide is understood to work
• Research summaries — condensed findings from the cited literature
• Reported study ranges — ranges as reported in studies, not recommended doses
• Risks — safety considerations noted in the research
• Regulatory status — where the compound stands legally

The site frames the whole compendium as "evidence-based profiles with mechanisms, research context, risks, and regulatory status," sourced from peer-reviewed research. That framing matters because it tells you what the site is not: it is not a dosing calculator, a vendor, or a forum of anecdotal reports.

How sourcing is surfaced per compound

The clearest sourcing signal is the per-profile citation count shown next to each entry. On the homepage alone:

These counts appear alongside the profile link, so you can compare documentation depth across compounds before opening anything. A profile with more cited sources generally means more underlying literature to draw on — though the count alone doesn't tell you the quality or recency of those sources, only the volume the editors attached to the entry.

Beyond individual profiles

PeptaHub layers additional reference material on top of the per-compound pages:

• Regulatory status tracker — described as per-compound and sourced
• FDA regulatory timeline (2023 to 2026) — a dated regulatory reference
• Editorial hubs — grouped collections such as GLP-1 Peptides (29 profiles), Recovery Peptides (9), Longevity Peptides (23), GH Secretagogues (27), Nootropic Peptides (25), Skin Peptides (23), and Immune Peptides (24)
• Head-to-head comparisons — e.g., BPC-157 vs TB-500, Semaglutide vs Tirzepatide, Retatrutide vs Tirzepatide

The site reports a total scope of 156 profiles across 10 categories and 7 hubs, drawing on 500+ sources.

What this means for judging credibility

The sourcing model gives you two practical checks:

1. Source count per profile — a fast proxy for how much literature backs a compound. BPC-157's 7 sources versus Semaglutide's 5, for instance, tells you the recovery peptide has more citations attached on this site, not that it has stronger clinical evidence overall.
2. Content type — mechanisms, research context, risks, and regulatory status are the stated components. If a profile lacks these, it falls short of the site's own standard.

One caveat worth holding onto: "peer-reviewed sources" describes where the material comes from, not the strength of the underlying evidence. A compound can have several peer-reviewed sources and still be early-stage or preclinical. The site's own categories — research context, reported study ranges, regulatory status — are where that distinction should show up, so read those sections rather than relying on the citation count alone.

If you want to see the sourcing model in action, start with a profile that lists its sources and compare it against a head-to-head page, where two compounds' evidence bases are placed side by side.